Incyte (NASDAQ:INCY) and Syndax Pharmaceuticals (SNDX) have received FDA approval for their drug Niktimvo in 9 mg and 22 mg vial sizes.

Niktimvo was approved in August 2024 for the treatment of chronic graft-versus-host disease after failure of at least